Medicenna Therapeutics Corp. (TSX:MDNA)
Canada · Delayed Price · Currency is CAD | Market Cap | 37.54M -55.0% |
| Revenue (ttm) | n/a |
| Net Income | -12.99M |
| EPS | -0.16 |
| Shares Out | 83.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 188,535 |
| Average Volume | 133,870 |
| Open | 0.4600 |
| Previous Close | 0.4550 |
| Day's Range | 0.4400 - 0.4600 |
| 52-Week Range | 0.4175 - 1.9700 |
| Beta | 1.91 |
| RSI | 33.65 |
| Earnings Date | Jun 26, 2026 |
About Medicenna Therapeutics
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multi... [Read more]
Financial Performance
Financial StatementsNews
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Compa...
Medicenna Announces the Launch of a Marketed Public Offering of Securities
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Compa...
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/...
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
Medicenna Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
MDNA11 is showing strong response rates in solid tumors, with pivotal trial planning underway. MDNA113, a novel bispecific anti-PD-1, demonstrated superior safety and efficacy in preclinical models and is set for clinical entry by year-end. MDNA55 is advancing toward phase III with a partner.
Medicenna Therapeutics presents new preclinical data from MDNA113
Medicenna Therapeutics (MDNAF) presented new positive preclinical data from MDNA113, its first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at the Ameri...
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenviro...
Medicenna Therapeutics Slides: Corporate presentation
Medicenna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Medicenna Therapeutics Announces Participation in Upcoming Conferences
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics reports Q3 EPS (5c) vs. (7c) last year
“We delivered strong clinical results in 2025 with our ABILITY-1 trial and 2026 is shaping up to be a milestone-rich year across our pipeline,” said Dr Fahar Merchant, President and…
Medicenna Therapeutics sees cash runway into 3Q26
Medicenna exited the quarter ended December 31, 2025, with cash and cash equivalents of $10.6 million. Based on the Company’s current operating plan, these funds are expected to be sufficient…
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026
Medicenna Therapeutics appoints Richard Sutin, Angelos Georgakis to board
Medicenna Therapeutics (MDNAF) announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company. Mr.
Medicenna Announces Changes to Board Composition
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics Earnings release: Q3 2026
Medicenna Therapeutics released its Q3 2026 earnings on February 13, 2026, summarizing the period's financial results.
Medicenna Therapeutics Registration statement: Q3 2026
Medicenna Therapeutics filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Medicenna Therapeutics Registration statement: Q3 2026
Medicenna Therapeutics filed a registration statement on February 13, 2026, providing details about a securities offering with the SEC.
Medicenna Therapeutics announces key milestones for 2026
Medicenna announces key milestones for 2026: Complete patient enrollment in ABILITY-1 study in MDNA11 monotherapy and combination arms across prioritized indications; Report updated clinical data from...
Medicenna Therapeutics highlights advancements in key programs
Medicenna Therapeutics (MDNAF) highlights significant advancements in its key programs. Key highlights include: Among monotherapy expansion cohorts, ORR was 50% in patients treated with MDNA11 in 2L/3...
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential fo...
Medicenna Therapeutics Transcript: KOL Event
MDNA11 demonstrated strong efficacy and a favorable safety profile in refractory solid tumors, with durable responses and high disease control rates in post-checkpoint inhibitor settings. KOLs highlighted its best-in-class potential and recommended expanding key cohorts and combination studies.
Medicenna Therapeutics Press release: KOL Event
Medicenna Therapeutics issued a press release on December 10, 2025, disclosing material business information to investors.
Medicenna Therapeutics Slides: KOL Event
Medicenna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on December 10, 2025.
Medicenna Therapeutics presents updated clinical data on MDNA11
Medicenna Therapeutics (MDNAF) presented updated clinical data from the ongoing Phase 1/2 ABILITY-1 study evaluating MDNA11 in patients with advanced solid tumors at the European Society of Medical On...